Abstract
Objective: The aim of this study was to review the role of activated carbon (AC) in eliminating the interference of rivaroxaban in the detection of lupus anticoagulants (LAs). Methods: Normal pooled plasma was obtained as group N1, group N2 took 1 mL plasma from N1 and added AC, group N3 was prepared by mixing normal plasma with rivaroxaban, and group N3 was treated with AC according to our procedure, as group N4. Plasma from 22 patients was collected before and 6–12 h after rivaroxaban therapy, described as group P1 and group P2, respectively, and 1 mL plasma was taken from group P2 and treated with AC, as group P3. Anti-Xa and diluted Russell’s viper venom time (dRVVT)/silica clotting time (SCT) index in each group were measured and compared. Results: Rivaroxaban concentrations and anti-Xa had high intercorrelations in group N3, and the levels of anti-Xa and dRVVT/SCT index had high intercorrelations. After treatment with AC, influence of rivaroxaban was removed, with LA and coagulation factor assays not influenced. Rivaroxaban administration could affect LA assay results in patients, with all LA results increased. After treatment with AC, results of anti-Xa and LA tests recovered to the level before rivaroxaban therapy. Conclusions: We proposed a reference procedure for the LA detection of patients using rivaroxaban by AC, and activated carbon was proven to be a simple product to eliminate the interference of rivaroxaban.
References
1.
Kershaw
G
, Suresh
S
, Orellana
D
, Nguy
YM
. Laboratory identification of lupus anticoagulants
. Semin Thromb Hemost
. 2012 Jun
;38
(04
):375
–84
. .2.
Shovman
O
, Gilburd
B
, Barzilai
O
, Langevitz
P
, Shoenfeld
Y
. Novel insights into associations of antibodies against cardiolipin and beta2-glycoprotein I with clinical features of antiphospholipid syndrome
. Clin Rev Allergy Immunol
. 2007
;32
(2
):145
–52
. .3.
Rasool
ZS
, Tiwari
V
. Biochemistry, lupus anticoagulant
. StatPearls [Internet]
. 2021 Jan
.4.
Garcia
D
, Erkan
D
. Diagnosis and management of the antiphospholipid syndrome
. N Engl J Med
. 2018 May 24
;379
(21
):1290
–21
. .5.
Devreese
KMJ
, de Groot
PG
, de Laat
B
, Erkan
D
, Favaloro
EJ
, Mackie
I
, Guidance from the scientific and standardization committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis: update of the guidelines for lupus anticoagulant detection and interpretation
. J Thromb Haemost
. 2020 Nov
;18
(11
):2828
–39
. .6.
Favaloro
EJ
. Variability and diagnostic utility of antiphospholipid antibodies including lupus anticoagulants
. Int J Lab Hematol
. 2013
;35
(3
):269
–74
. .7.
Moore
GW
. Recent guidelines and recommendations for laboratory detection of lupus anticoagulant
. Semin Thromb Hemost
. 2014, Mar
;40
(2
):163
–71
. .8.
Flieder
T
, Weiser
M
, Eller
T
, Dittrich
M
, von Bargen
K
, Alban
S
, Interference of DOACs in different DRVVT assays for diagnosis of lupus anticoagulants
. Thromb Res
. 2018 May
;165
:101
–6
. .9.
Lakos
G
. Interference in antiphospholipid antibody assays
. Semin Thromb Hemost
. 2012 Jun
;38
(4
):353
–9
. .10.
Kvasnicka
T
, Malikova
I
, Zenahlikova
Z
, Kettnerova
K
, Brzezkova
R
, Zima
T
, Rivaroxaban: metabolism, pharmacologic properties and drug interactions
. Curr Drug Metab
. 2017
;18
(7
):636
–42
. .11.
Guimarães
HP
, Lopes
RD
, de Barros E Silva
PG
, Liporace
IL
, Sampaio
RO
, Tarasoutchi
F
, Rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve
. N Engl J Med
. 2020
;383
(22
):2117
–26
.12.
Martinuzzo
ME
, Barrera
LH
, D’ adamo
MA
, Otaso
JC
, Gimenez
MI
, Oyhamburu
J
. Frequent false-positive results of lupus anticoagulant tests in plasmas of patients receiving the new oral anticoagulants and enoxaparin
. Int J Lab Hematol
. 2014 Apr
;36
(2
):144
–50
. .13.
Arachchillage
DR
, Mackie
IJ
, Efthymiou
M
, Isenberg
DA
, Machin
SJ
, Cohen
H
. Interactions between rivaroxaban and antiphospholipid antibodies in thrombotic antiphospholipid syndrome
. J Thromb Haemost
. 2015 Jul
;13
(7
):1264
–73
. .14.
Van Os
GM
, de Laat
B
, Kamphuisen
PW
, Meijers
JC
, de Groot
PG
. Detection of lupus anticoagulant in the presence of rivaroxaban using Taipan snake venom time
. J Thromb Haemost
. 2011 Aug
;9
(8
):1657
–9
. .15.
Hoxha
A
, Banzato
A
, Ruffatti
A
, Pengo
V
. Detection of lupus anticoagulant in the era of direct oral anticoagulants
. Autoimmun Rev
. 2017 Feb
;16
(2
):173
–8
. .16.
De Kesel
PM
, Devreese
KMJ
. Direct oral anticoagulant adsorption: impact on lupus anticoagulant testing-Review of the literature and evaluation on spiked and patient samples
. J Thromb Haemost
. 2020 Aug
;18
(8
):2003
–17
. .17.
Reda
S
, Brügelmann
A
, Müller
J
, Oldenburg
J
, Pötzsch
B
, Rühl
H
. Functional lupus anticoagulant testing in a large retrospective cohort of thrombosis patients with direct oral anticoagulants
. Sci Rep
. 2020 Jul 22
;10
(1
):12221
. .18.
Siriez
R
, Dogné
JM
, Gosselin
R
, Laloy
J
, Mullier
F
, Douxfils
J
. Comprehensive review of the impact of direct oral anticoagulants on thrombophilia diagnostic tests: Practical recommendations for the laboratory
. Int J Lab Hematol
. 2021 Feb
;43
(1
):7
–20
. .19.
European medecines agency summary of product characteristics, rivaroxaban. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000944/human_med_001155.jsp&mid=WC0b01ac058001d124 (accessed May 05, 2016).
20.
Douxfils
J
, Adcock
DM
, Bates
SM
, Favaloro
EJ
, Gouin-Thibault
I
, Guillermo
C
, 2021 update of the international council for standardization in haematology recommendations for laboratory measurement of direct oral anticoagulants
. Thromb Haemost
. 2021 Mar 19
;121
(8
):1008
–20
.21.
Ząbczyk
M
, Kopytek
M
, Natorska
J
, Undas
A
. The effect of DOAC-Stop on lupus anticoagulant testing in plasma samples of venous thromboembolism patients receiving direct oral anticoagulants
. Clin Chem Lab Med
. 2019 Aug 27
;57
(9
):1374
–81
. .22.
Kopatz
WF
, Brinkman
HJM
, Meijers
JCM
. Use of DOAC Stop for elimination of anticoagulants in the thrombin generation assay
. Thromb Res
. 2018 Oct
;170
:97
–101
. .23.
Exner
T
, Rigano
J
, Favaloro
EJ
. The effect of DOACs on laboratory tests and their removal by activated carbon to limit interference in functional assays
. Int J Lab Hematol
. 2020 Jun
;42
(Suppl 1
):41
–8
. .© 2022 S. Karger AG, Basel
2022
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
